

**AMENDMENTS TO THE CLAIMS**

Please amend the claims to read as follows:

1 - 15 (cancelled)

16. (Currently amended) A method for treating undesirable cell proliferation associated with mycoplasma infection in a subject comprising administering to the subject an effective amount of an agent that ~~prevents or~~ inhibits sialic acid-mediated attachment of mycoplasma to cells of the subject, wherein the agent is an antibiotic.

17. (cancelled)

18. (cancelled)

19. (cancelled)

20. (cancelled)

21. (Previously presented) The method of claim 16, wherein the undesirable cell proliferation is a manifestation of a disease selected from the group consisting of ~~atherosclerosis~~, ovarian carcinoma, breast cancer, prostate cancer, colon cancer, lung cancer, pancreatic cancer, gastric cancer, thyroid cancer, melanoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma and testicular carcinoma.

22. (New) The method of claim 16, wherein the undesirable cell proliferation is atherosclerosis.

23. (New) A method for treating undesirable cell proliferation associated with mycoplasma infection in a subject comprising administering to the subject an effective amount of an agent that inhibits sialic acid-mediated attachment of mycoplasma to cells of the subject, wherein the agent is selected from the group consisting of an enzyme

having trans-sialidase activity, and an enzyme having neuraminidase activity, and a combination thereof.

24. (New) The method of claim 23, wherein the enzyme is obtained from *Trypanosoma cruzi*.

25. (New) The method of claim 24, wherein the enzyme has an amino acid sequence set forth in SEQ ID NO:2.

26. (New) The method of claim 23, wherein the disorder is atherosclerosis.

27. (New) The method of claim 23, wherein the disorder is malignancy.